SCHEDULE: Intracoastal Capital Discloses 4.99% Stake in Soligenix

Intracoastal Capital, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Soligenix, Inc. as of October 1, 2025.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G for Soligenix, Inc.
• As of October 1, 2025, the Reporting Persons beneficially own an aggregate of 446,408 shares of Soligenix Common Stock.
• This ownership represents approximately 4.99% of the outstanding Common Stock of Soligenix, Inc.
• The shares are primarily issuable upon the exercise of Intracoastal Warrant 2.
• The beneficial ownership percentage is capped at 4.99% due to blocker provisions within the warrants, preventing the holder from exceeding this threshold.
• Initially, following a Securities Purchase Agreement (SPA) on September 25, 2025, the Reporting Persons were deemed to have beneficial ownership of 477,865 shares (approximately 9.99%), including shares to be issued and shares from Intracoastal Warrant 1.
• The reported ownership is based on 4,305,570 shares of Common Stock outstanding as of September 25, 2025, plus additional shares issued subsequently.

Sentiment

Score: 6

Explanation: The filing indicates increased institutional interest and an implied capital raise for Soligenix, which is generally a positive signal, though the passive nature of the stake limits direct influence.

Positives

• Increased institutional investor interest in Soligenix, Inc. from Intracoastal Capital and its principals.
• The filing indicates a recent capital raise by Soligenix through a Securities Purchase Agreement and warrant issuance, providing the company with funding.

Future Outlook

This filing does not provide specific forward-looking statements or guidance from Soligenix, Inc. It primarily details the beneficial ownership stake of the Reporting Persons.

Management Comments

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Soligenix, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The disclosure of a significant passive stake by an institutional investor like Intracoastal Capital in a biotechnology company such as Soligenix is a common occurrence, often following a financing round. Such investments can signal confidence in the company's long-term prospects or specific pipeline developments, aligning with broader trends of institutional capital flowing into the life sciences sector.

Stakeholder Impact

• Shareholders: The entry of a new institutional investor and the implied capital raise could be viewed positively, potentially increasing liquidity and validating the company's strategy.
• Company: The capital raise provides funding for operations and development, while the passive nature of the investment means no immediate changes to corporate control or strategy are expected from these investors.

Key Dates

Recommendation

The disclosure of a new 4.99% passive stake by an institutional investor, Intracoastal Capital, following a recent capital raise, generally signals a vote of confidence in Soligenix. While a Schedule 13G does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation, the increased institutional interest and implied funding are positive indicators. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring future company developments and financial reports for more comprehensive insights.

Keywords

Soligenix, Intracoastal Capital, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, SEC Filing, Warrants